Cancer as a robust system: implications for anticancer therapy
暂无分享,去创建一个
[1] R L Juliano,et al. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. , 1976, Biochimica et biophysica acta.
[2] Goldie Jh,et al. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. , 1979 .
[3] J H Goldie,et al. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. , 1979, Cancer treatment reports.
[4] T. Tsuruo,et al. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. , 1981, Cancer research.
[5] V. Ling,et al. Metastatic variants are generated spontaneously at a high rate in mouse KHT tumor. , 1982, Proceedings of the National Academy of Sciences of the United States of America.
[6] J H Goldie,et al. The genetic origin of drug resistance in neoplasms: implications for systemic therapy. , 1984, Cancer research.
[7] J. F. Harris,et al. Dynamic heterogeneity and metastasis , 1984, Journal of cellular physiology. Supplement.
[8] H. Skipper,et al. Tumor stem cell heterogeneity: implications with respect to classification of cancers by chemotherapeutic effect. , 1984, Cancer treatment reports.
[9] Skipper He,et al. Tumor stem cell heterogeneity: implications with respect to classification of cancers by chemotherapeutic effect. , 1984 .
[10] V. Ling,et al. Dynamic heterogeneity: rapid generation of metastatic variants in mouse B16 melanoma cells. , 1984, Science.
[11] P. Nowell. Mechanisms of tumor progression. , 1986, Cancer research.
[12] [Chronobiology and cancer]. , 1987, Pathologie-biologie.
[13] V. Ling,et al. Dynamic heterogeneity: characterization of two cell lines derived from experimental lung metastases of mouse KHT fibrosarcoma. , 1987, Invasion & metastasis.
[14] B. Vogelstein,et al. A genetic model for colorectal tumorigenesis , 1990, Cell.
[15] C. Seynaeve,et al. A phase II study of epidoxorubicin in colorectal cancer and the use of cyclosporin-A in an attempt to reverse multidrug resistance. , 1991, British Journal of Cancer.
[16] C. Seynaeve,et al. Short report: Phase II study of combining vinblastine and cyclosporin-A to circumvent multidrug resistance in renal cell cancer , 1991 .
[17] H. Herweijer,et al. Multidrug resistance (mdr) genes in human cancer. , 1991, British Journal of Cancer.
[18] Phase II study of combining vinblastine and cyclosporin-A to circumvent multidrug resistance in renal cell cancer. , 1991, Annals of oncology : official journal of the European Society for Medical Oncology.
[19] J. Schornagel,et al. Clinical pharmacokinetics of anti-metabolites. , 1993, Cancer surveys.
[20] M. Eigen. Viral quasi species. , 1993 .
[21] M. Eigen,et al. Viral quasispecies. , 1993, Scientific American.
[22] Lars Holmgren,et al. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression , 1995, Nature Medicine.
[23] C. Murray. Tumour dormancy: not so sleepy after all , 1995, Nature Medicine.
[24] J. Folkman,et al. Angiostatin induces and sustains dormancy of human primary tumors in mice , 1996, Nature Medicine.
[25] M. Goldberg,et al. Hypoxia-inducible Protein Binding to Vascular Endothelial Growth Factor mRNA and Its Modulation by the von Hippel-Lindau Protein* , 1996, The Journal of Biological Chemistry.
[26] A. Giaccia,et al. Oncogenic transformation and hypoxia synergistically act to modulate vascular endothelial growth factor expression. , 1996, Cancer research.
[27] P Vaupel,et al. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. , 1996, Cancer research.
[28] P. Sismondi,et al. Lack of effectiveness of adjuvant alternating chemotherapy in node-positive, estrogen-receptor-negative premenopausal breast cancer patients: results of a multicentric Italian study. The Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group (GROCTA). , 1997, Cancer investigation.
[29] S. Leibler,et al. Robustness in simple biochemical networks , 1997, Nature.
[30] Thomas Boehm,et al. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance , 1997, Nature.
[31] R. Scheuermann,et al. Cancer dormancy: Opportunities for new therapeutic approaches , 1997, Nature Medicine.
[32] M. Bader,et al. Less efficacy with alternating regimen as adjuvant chemotherapy in stage II node-positive breast cancer: results at 8 years (Pronacam 85). , 1997, British Journal of Cancer.
[33] A. Arkin,et al. Stochastic mechanisms in gene expression. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[34] W. Risau,et al. Activator-protein-1 binding potentiates the hypoxia-induciblefactor-1-mediated hypoxia-induced transcriptional activation of vascular-endothelial growth factor expression in C6 glioma cells. , 1997, The Biochemical journal.
[35] A. Arkin,et al. Simulation of prokaryotic genetic circuits. , 1998, Annual review of biophysics and biomolecular structure.
[36] A. Andrén-sandberg,et al. Cytogenetic analysis of pancreatic carcinomas: Intratumor heterogeneity and nonrandom pattern of chromosome aberrations , 1998, Genes, chromosomes & cancer.
[37] K. Kinzler,et al. Genetic instabilities in human cancers , 1998, Nature.
[38] S. Kaye. Multidrug resistance: clinical relevance in solid tumours and strategies for circumvention. , 1998, Current opinion in oncology.
[39] A. Giaccia,et al. The complexity of p53 modulation: emerging patterns from divergent signals. , 1998, Genes & development.
[40] M. B,et al. Bifurcation Analysis of a Model of Mitotic Control in Frog Eggs , 1998 .
[41] C Lengauer,et al. Genetic instability and darwinian selection in tumours. , 1999, Trends in cell biology.
[42] J. W. Little,et al. Robustness of a gene regulatory circuit , 1999, The EMBO journal.
[43] A. Arkin,et al. It's a noisy business! Genetic regulation at the nanomolar scale. , 1999, Trends in genetics : TIG.
[44] U. Alon,et al. Robustness in bacterial chemotaxis , 2022 .
[45] J M Carlson,et al. Highly optimized tolerance: a mechanism for power laws in designed systems. , 1999, Physical review. E, Statistical physics, plasmas, fluids, and related interdisciplinary topics.
[46] L. Ossowski,et al. Tumor Dormancy Induced by Downregulation of Urokinase Receptor in Human Carcinoma Involves Integrin and MAPK Signaling , 1999, The Journal of cell biology.
[47] Yusuke Nakamura,et al. A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage , 2000, Nature.
[48] R. Hruban,et al. Frequent genetic heterogeneity in the clonal evolution of gynecological carcinosarcoma and its influence on phenotypic diversity. , 2000, Cancer research.
[49] L. Mayer,et al. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[50] I. Weinstein. Disorders in cell circuitry during multistage carcinogenesis: the role of homeostasis. , 2000, Carcinogenesis.
[51] L. Guarente,et al. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase , 2000, Nature.
[52] U Alon,et al. Generation of oscillations by the p53-Mdm2 feedback loop: a theoretical and experimental study. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[53] G. Odell,et al. The segment polarity network is a robust developmental module , 2000, Nature.
[54] Hui Wang,et al. MDM2 oncogene as a novel target for human cancer therapy. , 2000, Current pharmaceutical design.
[55] Albert-László Barabási,et al. Error and attack tolerance of complex networks , 2000, Nature.
[56] A. Levine,et al. Surfing the p53 network , 2000, Nature.
[57] J. Levine,et al. Surfing the p53 network , 2000, Nature.
[58] R. Albert,et al. The large-scale organization of metabolic networks , 2000, Nature.
[59] L. Guarente,et al. Sir2 links chromatin silencing, metabolism, and aging. , 2000, Genes & development.
[60] P. Duesberg,et al. Aneuploidy, the somatic mutation that makes cancer a species of its own. , 2000, Cell motility and the cytoskeleton.
[61] P. Duesberg,et al. Aneuploidy vs. gene mutation hypothesis of cancer: recent study claims mutation but is found to support aneuploidy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[62] J. Doyle,et al. Robust perfect adaptation in bacterial chemotaxis through integral feedback control. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[63] G. Naumov,et al. Solitary cancer cells as a possible source of tumour dormancy? , 2001, Seminars in cancer biology.
[64] M J Bissell,et al. Tumors are unique organs defined by abnormal signaling and context. , 2001, Seminars in cancer biology.
[65] A. Andrén-sandberg,et al. Extensive cytogenetic heterogeneity in a benign retroperitoneal schwannoma. , 2001, Cancer genetics and cytogenetics.
[66] V. Schirrmacher. T-cell immunity in the induction and maintenance of a tumour dormant state. , 2001, Seminars in cancer biology.
[67] A. Levine,et al. The p53 functional circuit. , 2001, Journal of cell science.
[68] Delin Chen,et al. Negative Control of p53 by Sir2α Promotes Cell Survival under Stress , 2001, Cell.
[69] F T Bosman,et al. Intratumor genetic heterogeneity in advanced human colorectal adenocarcinoma , 2001, International journal of cancer.
[70] M. Shah,et al. Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[71] W. Falk,et al. A primary tumor promotes dormancy of solitary tumor cells before inhibiting angiogenesis. , 2001, Cancer research.
[72] H. Kitano,et al. Robust oscillations within the interlocked feedback model of Drosophila circadian rhythm. , 2001, Journal of theoretical biology.
[73] T. Mcclanahan,et al. Involvement of chemokine receptors in breast cancer metastasis , 2001, Nature.
[74] M. Blagosklonny,et al. Exploiting cancer cell cycling for selective protection of normal cells. , 2001, Cancer research.
[75] L. Mayer,et al. Modulation of P-glycoprotein (PGP) mediated multidrug resistance (MDR) using chemosensitizers: recent advances in the design of selective MDR modulators. , 2001, Current medicinal chemistry. Anti-cancer agents.
[76] P Vaupel,et al. Biological consequences of tumor hypoxia. , 2001, Seminars in oncology.
[77] I. Weissman,et al. Stem cells, cancer, and cancer stem cells , 2001, Nature.
[78] P. Vaupel,et al. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. , 2001, Journal of the National Cancer Institute.
[79] J. Aguirre-Ghiso,et al. Urokinase receptor and fibronectin regulate the ERK(MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo. , 2001, Molecular biology of the cell.
[80] P. N. Rao,et al. Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.
[81] Mina J. Bissell,et al. Putting tumours in context , 2001, Nature Reviews Cancer.
[82] B. Druker,et al. Roots of Clinical Resistance to STI-571 Cancer Therapy , 2001, Science.
[83] Elise C. Kohn,et al. The microenvironment of the tumour–host interface , 2001, Nature.
[84] John Doyle,et al. Complexity and robustness , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[85] Adrian L. Harris,et al. Hypoxia — a key regulatory factor in tumour growth , 2002, Nature Reviews Cancer.
[86] A. Zlotnik,et al. Chemokines: agents for the immunotherapy of cancer? , 2002, Nature Reviews Immunology.
[87] R. Solé,et al. Metapopulation dynamics and spatial heterogeneity in cancer , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[88] J. Drevs,et al. Antiangiogenesis: Current Clinical Data and Future Perspectives , 2002, Oncology Research and Treatment.
[89] Manfred Eigen,et al. Error catastrophe and antiviral strategy , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[90] P. Nowell. Tumor progression: a brief historical perspective. , 2002, Seminars in cancer biology.
[91] Jeff Hasty,et al. Engineered gene circuits , 2002, Nature.
[92] C. Rao,et al. Control, exploitation and tolerance of intracellular noise , 2002, Nature.
[93] Pablo A. Parrilo,et al. Introducing SOSTOOLS: a general purpose sum of squares programming solver , 2002, Proceedings of the 41st IEEE Conference on Decision and Control, 2002..
[94] G. Odell,et al. Robustness, Flexibility, and the Role of Lateral Inhibition in the Neurogenic Network , 2002, Current Biology.
[95] J. Doyle,et al. Robustness as a measure of plausibility in models of biochemical networks. , 2002, Journal of theoretical biology.
[96] A. Harris,et al. Hypoxia‐induced pathways in breast cancer , 2002, Microscopy research and technique.
[97] P. Klatt,et al. 'Super p53' mice exhibit enhanced DNA damage response, are tumor resistant and age normally , 2002, The EMBO journal.
[98] I. Weinstein. Addiction to Oncogenes--the Achilles Heal of Cancer , 2002, Science.
[99] H. Kitano. Systems Biology: A Brief Overview , 2002, Science.
[100] G. Naumov,et al. Persistence of solitary mammary carcinoma cells in a secondary site: a possible contributor to dormancy. , 2002, Cancer research.
[101] D. Rasnick. Aneuploidy theory explains tumor formation, the absence of immune surveillance, and the failure of chemotherapy. , 2002, Cancer genetics and cytogenetics.
[102] Jeffrey S. Smith. Human Sir2 and the 'silencing' of p53 activity. , 2002, Trends in cell biology.
[103] Kenneth Chu,et al. Sustained Loss of a Neoplastic Phenotype by Brief Inactivation of MYC , 2002, Science.
[104] Hiroaki Kitano,et al. Cancer robustness: Tumour tactics , 2003, Nature.
[105] C. Parish. Cancer immunotherapy: The past, the present and the future , 2003, Immunology and cell biology.
[106] H. Moch,et al. Chemokine receptor CXCR4 downregulated by von Hippel–Lindau tumour suppressor pVHL , 2003, Nature.
[107] A. Hochhaus. Cytogenetic and molecular mechanisms of resistance to imatinib. , 2003, Seminars in hematology.
[108] D. Berrigan,et al. Calorie restriction, aging, and cancer prevention: mechanisms of action and applicability to humans. , 2003, Annual review of medicine.
[109] L. Guarente,et al. How does calorie restriction work? , 2003, Genes & development.
[110] E. Eigenbrodt,et al. The tumor metabolome. , 2003, Anticancer research.
[111] K. Loeb,et al. Multiple mutations and cancer , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[112] P. Carli,et al. Immediate local and regional recurrence after the excision of a polypoid melanoma: tumor dormancy or tumor activation? , 2003, Dermatologic Surgery.
[113] G. Semenza. Targeting HIF-1 for cancer therapy , 2003, Nature Reviews Cancer.
[114] J. Tischfield,et al. Somatic recombination redux , 2003, Nature Genetics.
[115] J. Aguirre-Ghiso,et al. ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK). , 2003, Cancer research.
[116] Mina J Bissell,et al. Tumor reversion: Correction of malignant behavior by microenvironmental cues , 2003, International journal of cancer.
[117] A. Papachristodoulou,et al. Analysis of switched and hybrid systems - beyond piecewise quadratic methods , 2003, Proceedings of the 2003 American Control Conference, 2003..
[118] M. Hiraoka,et al. Tumor hypoxia: A target for selective cancer therapy , 2003, Cancer science.
[119] J. Aguirre-Ghiso,et al. ERKMAPK Activity as a Determinant of Tumor Growth and Dormancy; Regulation by p38SAPK , 2003 .
[120] Ricard V. Solé,et al. Phase transitions in unstable cancer cell populations , 2003 .
[121] J. Denu. Linking chromatin function with metabolic networks: Sir2 family of NAD(+)-dependent deacetylases. , 2003, Trends in biochemical sciences.
[122] Mattias Höglund,et al. Power law distribution of chromosome aberrations in cancer. , 2003, Cancer research.
[123] Giuseppe Tonini,et al. Cancer chronotherapy: Principles, applications, and perspectives , 2003, Cancer.
[124] D. Lane,et al. The p53-Mdm2 pathway: targets for the development of new anticancer therapeutics. , 2003, Mini reviews in medicinal chemistry.
[125] K. Haigis,et al. A Robertsonian translocation suppresses a somatic recombination pathway to loss of heterozygosity , 2003, Nature Genetics.
[126] L. Ellis,et al. Promises and pitfalls of anti-angiogenic therapy in clinical trials. , 2003, Trends in molecular medicine.
[127] P. Comoglio,et al. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. , 2003, Cancer cell.
[128] M. Feuerer,et al. T Cell Memory, Anergy and Immunotherapy in Breast Cancer , 2002, Journal of Mammary Gland Biology and Neoplasia.
[129] J. Spalding,et al. Toward a chronotherapy of neoplasia: Tolerance of treatment depends upon host rhythms , 1973, Experientia.
[130] M. Falk. Human Sir 2 and the ‘ silencing ’ of p 53 activity , 2022 .
[131] R. Huber,et al. Transcriptional silencing and longevity protein Sir 2 is an NAD-dependent histone deacetylase , 2022 .